Story perspectives

Sanofi Sales Surge 11.3% Fueled by Dupixent and Beyfortus

1/30/2025

50 8

Summary

Story summary

Sanofi achieved an 11.3% sales increase in 2024, reaching €41 billion ($42.7 billion), primarily from Dupixent's €13 billion ($13.62 billion) sales.
The new RSV vaccine, Beyfortus, generated €1.7 billion ($1.77 billion) in its first year.
The R&D budget will rise by 14.6% to €7.4 billion ($7.72 billion) as Sanofi divests from consumer healthcare.
Continued growth is expected in 2025, driven by Dupixent's expansion into COPD and a robust vaccine pipeline.

1 of 1

Story summary

Sanofi achieved an 11.3% sales increase in 2024, reaching €41 billion ($42.7 billion), primarily from Dupixent's €13 billion ($13.62 billion) sales.
The new RSV vaccine, Beyfortus, generated €1.7 billion ($1.77 billion) in its first year.
The R&D budget will rise by 14.6% to €7.4 billion ($7.72 billion) as Sanofi divests from consumer healthcare.
Continued growth is expected in 2025, driven by Dupixent's expansion into COPD and a robust vaccine pipeline.